FORMULATIONS FOR NUTRITIONAL SUPPORT IN SUBJECTS IN NEED THEREOF
Formulations having a protein component, in which the protein contains one or more digestion-aiding proteins, and one or more immunoprotective proteins. The ratio by weight of the one or digestion-aiding proteins to the one or more immunoprotective proteins may be about 12:1 to about 1:1. The formulations may also contain a fat component, a carbohydrate component, and vitamins and minerals. These formulations can be used to provide nutritional support to a subject, either as dietary supplements or as a primary source of nutrition, such as for an infant formula. The formulations may also be used to promote or induce proliferation of intestinal cells, promote or induce differentiation of intestinal cells, prevent or inhibit growth of enteropathogenic Escherichia coli in the digestive system of a subject, prevent or inhibit bacterial growth in the intestinal lumen, increase interleukin-18 secretion by intestinal cells, or increase intestinal immunity.
1 . A formulation for oral administration comprising a protein component, wherein the protein component comprises:
(a) lactoferrin, and
(b) osteopontin;
wherein the ratio by weight of the lactoferrin to the osteopontin is about 12:1 to about 2:1.
2 . The formulation of claim 1 , wherein the ratio by weight of the lactoferrin to the osteopontin is about 10:1 to about 3:1.
3 . The formulation of claim 1 , wherein the formulation further comprises one or more digestion-aiding proteins.
4 . The formulation of claim 3 , wherein the ratio by weight of the one or more digestion aiding proteins to the lactoferrin and osteopontin is about 12:1 to about 1:1.
5 . (canceled)
6 . The formulation of claim 3 , wherein the one or more digestion-aiding proteins comprise whey protein hydrolysate, alpha-lactalbumin, or a combination thereof.
7 . A formulation for oral administration comprising a protein component, wherein the protein component comprises:
(a) one or more digestion aiding proteins comprising whey protein hydrolysate, alpha-lactalbumin, or a combination thereof; and
(b) one or more immunoprotective proteins comprising lactoferrin, osteopontin, or a combination thereof;
wherein the ratio by weight of the one or more digestion aiding proteins to the one or more immunoprotective proteins is about 12:1 to about 1:1.
8 . The formulation of claim 7 , wherein the ratio by weight of the one or more digestion aiding proteins to the one or more immunoprotective proteins is about 10:1 to about 3:1.
9 . The formulation of claim 7 , wherein the one or more digestion aiding proteins comprises whey protein hydrolysate, and the one or more immunoprotective proteins comprises lactoferrin; and
wherein the ratio by weight of the whey protein hydrolysate to the lactoferrin is about 9:1 to about 1:1.
10 - 11 . (canceled)
12 . The formulation of claim 7 , wherein the one or more digestion aiding proteins comprises whey protein hydrolysate, and the one or more immunoprotective proteins comprises osteopontin; and
wherein the ratio by weight of the whey protein hydrolysate to the osteopontin is about 60:1 to about 10:1.
13 - 14 . (canceled)
15 . The formulation of claim 7 , wherein the one or more digestion aiding proteins comprises alpha-lactalbumin, and the one or more immunoprotective proteins comprises lactoferrin; and
wherein the ratio by weight of the alpha-lactalbumin to the lactoferrin is about 4:1 to about 0.5:1.
16 - 17 . (canceled)
18 . The formulation of claim 7 , wherein the one or more digestion aiding proteins comprises alpha-lactalbumin, and the one or more immunoprotective proteins comprises osteopontin; and
wherein the ratio by weight of the alpha-lactalbumin to the osteopontin is about 25:1 to about 5:1.
19 - 21 . (canceled)
22 . A method of providing nutritional support to a subject in need thereof, the method comprising administering to the subject a formulation according to claim 1 .
23 . A method of promoting proliferation of intestinal cells in a subject in need thereof, the method comprising administering to the subject a formulation according to claim 1 .
24 . A method of inducing proliferation of intestinal cells in a subject in need thereof, the method comprising administering to the subject a formulation according to claim 1 .
25 . A method of promoting differentiation of intestinal cells in a subject in need thereof, the method comprising administering to the subject a formulation according to claim 1 .
26 . A method of inducing differentiation of intestinal cells in a subject in need thereof, the method comprising administering to the subject a formulation according to claim 1 .
27 . (canceled)
28 . A method of inhibiting growth of enteropathogenic Escherichia coli in the digestive system of a subject in need thereof, the method comprising administering to the subject a formulation according to claim 1 .
29 . (canceled)
30 . A method of inhibiting bacterial infection in the intestinal lumen of a subject in need thereof, the method comprising administering to the subject a formulation according to claim 1 .
31 . A method of inhibiting growth of increasing interleukin-18 secretion by intestinal cells in a subject in need thereof, the method comprising administering to the subject a formulation according to claim 1 .
32 . A method of increasing intestinal immunity in a subject in need thereof, the method comprising administering to the subject a formulation according to claim 1 .
33 . A formulation for oral administration comprising a protein component, wherein the protein component comprises:
(a) one or more digestion aiding proteins comprising whey protein hydrolysate, alpha-lactalbumin, or a combination thereof; and
(b) lactoferrin;
wherein the ratio by weight of the one or more digestion aiding proteins to the lactoferrin is about 10:1 to about 0.5:1.
34 . The formulation of claim 33 , wherein the one or more digestion aiding proteins comprises whey protein hydrolysate; and
wherein the ratio by weight of the whey protein hydrolysate to the lactoferrin is about 9:1 to about 1:1.
35 . The formulation of claim 33 wherein the one or more digestion aiding proteins comprises alpha-lactalbumin; and
wherein the ratio by weight of the alpha-lactalbumin to the lactoferrin is about 4:1 to about 0.5:1.